Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.
Department of Neurology, Northern Health, Epping, Melbourne, VIC, 3076, Australia. ng.fcffelix@gmail.com.
Felix C
FC
Ng
Department of Neurology, Northern Health, Epping, Melbourne, VIC, 3076, Australia.
James
J
Bice
Department of Neurology, Northern Health, Epping, Melbourne, VIC, 3076, Australia.
Anne
A
Rodda
Department of Neurology, Northern Health, Epping, Melbourne, VIC, 3076, Australia.
Matthew
M
Lee-Archer
Department of Neurology, Northern Health, Epping, Melbourne, VIC, 3076, Australia.
Douglas E
DE
Crompton
D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000991:Antithrombins / Q000009:adverse effects* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy; D000069604:Dabigatran / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods
D061067:Antibodies, Monoclonal, Humanized; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran